Wednesday, November 11, 2026
22.6 C
Bengaluru

Shakul Srivastava has been appointed as Senior Vice President at Indian Immunologicals Limited.

With over three decades of experience in the pharmaceutical and healthcare industry, Shakul brings extensive expertise in vaccines, commercial leadership, business transformation, and strategic growth. His leadership journey has been focused on transforming businesses through strategic enablement, process efficiency, people development, market expansion, resource optimization, digital innovation, cultural integration, and effective P&L management.

In his current role at Indian Immunologicals Limited, he is responsible for leading the human vaccines business while driving strategic business initiatives and digital transformation. His focus includes fostering innovation, developing new concepts, and strengthening the organization’s capabilities in the vaccines segment.

Prior to this role, Shakul served as Vice President – Human Health at Indian Immunologicals, where he played a key role in establishing and expanding the company’s human vaccines, hormones, and wellness product portfolio. He also led large commercial teams across sales, marketing, learning and development, and business operations.

Free Membership Required

You must be a Free member to access this content.

Join Now

Already a member? Log in here

Hot this week

Evonile Pharma: The Real Bet Is Not the Acquisition. It is the Field Force.

ChrysCapital’s acquisition of Novartis India and its transformation into...

Closing the Value Gap in Indian Pharma: What Doctors Really Want from Digital Engagement

Indian pharma is investing heavily in digital engagement. But...

Indian Pharma 2026: The Growth Engine Is Changing

The Indian Pharmaceutical Market isn't just growing. Its centre...

Anand Shetty Appointed CEO – Emerging Markets at Cadila Pharmaceuticals

Cadila Pharmaceuticals has appointed Anand Shetty as Chief Executive...

The paradox of the “Pharmacy of the World.” 💊

India has world-scale formulation capability, yet the chemistry beneath...

Topics

Evonile Pharma: The Real Bet Is Not the Acquisition. It is the Field Force.

ChrysCapital’s acquisition of Novartis India and its transformation into...

Indian Pharma 2026: The Growth Engine Is Changing

The Indian Pharmaceutical Market isn't just growing. Its centre...

Anand Shetty Appointed CEO – Emerging Markets at Cadila Pharmaceuticals

Cadila Pharmaceuticals has appointed Anand Shetty as Chief Executive...

The paradox of the “Pharmacy of the World.” 💊

India has world-scale formulation capability, yet the chemistry beneath...

Private Equity in Indian Healthcare: Who Is Investing Beyond the Metros?

Private capital is transforming India's healthcare landscape. But is...
spot_img

Related Articles

spot_imgspot_img